Ireland· IE-PA-EU/1/16/1157/003-004
Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen
A insulin glargine product containing lixisenatide + insulin glargine, registered in Ireland by Sanofi-Aventis Groupe. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Insulin glargine is registered in 13 of 19 countries.
Countries holding a registration under ATC A10AE04 (insulin glargine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Insulin glargine · ATC A10AE04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Lixisenatide + Insulin glargine
- Manufacturer
- Sanofi-Aventis Groupe
- Country
- Ireland (IE)
- ATC code
- A10AE04
- ATC class
- Insulin glargine
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1157/003-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
433 interactions on record for insulin glargine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin glargine · interactions on record
433 records
- 15 severe
- 367 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin glargine in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSULIQUASanofi Winthrop Industrie, Gentilly
- PolandSuliquaSanofi Winthrop Industrie
- SwedenSuliqua 100 enheter/ml+33 mikrogram/ml Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- SpainSULIQUA 100 UNIDADES/ML + 33 MICROGRAMOS/ML SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- FinlandSuliquaSanofi Winthrop Industrie
- United KingdomSuliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pensSanofi
- SwitzerlandSuliqua 100/33, solution injectableSanofi-Aventis (Suisse) SA
- IcelandSuliquaSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Suliqua
- Liechtenstein · Suliqua
- Norway · Suliqua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0e66c34-c087-478a-aee7-65cc557001f2 GET /v1/drugs/d0e66c34-c087-478a-aee7-65cc557001f2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"A10AE",
"A10AE04"
],
"strength": null,
"pa_number": "EU/1/16/1157/003-004",
"substances": [
"Lixisenatide",
"Insulin glargine"
],
"legal_basis": "Fixed combination application (Article 10b of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "11/01/2017",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about insulin glargine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.